{"id":"W2888893923","doi":"10.1016/j.atherosclerosis.2018.08.036","title":"Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program","year":2018,"lang":"en","type":"article","venue":"Atherosclerosis","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Aegerion Pharmaceuticals; Seventh Framework Programme; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Orion Corporation; Amarin Corporation; Regeneron Pharmaceuticals; Sanofi; European Commission; Pfizer; Amgen","keywords":"Familial hypercholesterolemia; Alirocumab; Extension (predicate logic); Term (time); Medicine; Open label; Internal medicine; Adverse effect; Cholesterol; Computer science; Lipoprotein; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00212415,0.0005467731,0.000942334,0.0002143406,0.0003395116,0.0004097751,0.0003105279,0.0005521044,0.001880812],"category_scores_gemma":[0.001497671,0.0002220453,0.000918861,0.0001576222,0.000498091,0.0005702787,0.0004194939,0.001064292,0.000230889],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005161156,"about_ca_system_score_gemma":0.0009466923,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006627574,"about_ca_topic_score_gemma":0.0019208,"domain_scores_codex":[0.9993591,0.0003662712,0.00004760448,0.00009084829,0.00006362188,0.00007254761],"domain_scores_gemma":[0.9987954,0.000276107,0.0003598858,0.0001265946,0.0001055624,0.0003363955],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7761869,0.03305816,0.02140761,0.0006802352,0.0008455904,0.000228057,0.0005086014,0.0005436282,0.02425874,0.0001342379,0.001074457,0.1410737],"study_design_scores_gemma":[0.3917459,0.4935725,0.1024777,0.00007985825,0.001178265,0.0004586304,0.0001441112,0.001562476,0.005171764,0.0001201321,0.003441171,0.00004752646],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985307,0.0004094842,0.0002080596,0.00007616339,0.00001498209,0.0002977044,0.0001233949,0.00001716715,0.0003222227],"genre_scores_gemma":[0.9978173,0.0002916434,0.0007763603,0.0001492834,0.00004264793,0.0003510792,0.0002080744,0.000003811863,0.0003598739],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00212415,"threshold_uncertainty_score":0.01123369,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02839801831121224,"score_gpt":0.293402990230041,"score_spread":0.2650049719188288,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}